Cytokinetics Reports Strong MYQORZO Launch Momentum, Plans Expanded HCM Indication Filings

  • MYQORZO (aficamten) generated $44.5M in Q3 2026 revenue, with 2,800+ patients dispensed and 1,100+ prescribers
  • Company plans to submit Supplemental NDA for non-obstructive HCM in Q4 2026 and EU filing in early 2027
  • Cash position of $1.6B as of September 30, 2026, down from $1.7B in Q2 2026
  • Net loss of $190.1M in Q3 2026, narrower than $306.2M loss in Q3 2025
  • Reaffirmed 2026 guidance of $860M-$890M in combined R&D and SG&A expenses

Cytokinetics is transitioning from a development-stage company to a commercial player in specialty cardiology, with MYQORZO's launch showing early traction. The planned regulatory filings for non-obstructive HCM could position aficamten as the first therapy approved across the full spectrum of hypertrophic cardiomyopathy. The company's strong cash position provides runway for these strategic initiatives, though execution risks remain in both commercialization and pipeline development.

Regulatory Momentum
Whether Cytokinetics can secure approvals for aficamten in non-obstructive HCM by mid-2027, expanding its market opportunity
Commercial Scaling
The pace at which MYQORZO adoption accelerates beyond the U.S., particularly in Europe and other international markets
Pipeline Progress
How quickly omecamtiv mecarbil and ulacamten advance through clinical trials, diversifying revenue streams